Format
Items per page
Sort by

Send to:

Choose Destination

Links from PubMed

Items: 1 to 20 of 99

1.

Reduced expression of NDUFS3 and its clinical significance in serous ovarian cancer.

Wang P, Cheng X, Fu Z, Zhou C, Lu W, Xie X.

Int J Gynecol Cancer. 2013 May;23(4):622-9. doi: 10.1097/IGC.0b013e318287a90d.

PMID:
23446378
2.

Response on: reduced expression of NDUFS3 and its clinical significance in serous ovarian cancer.

Piek JM.

Int J Gynecol Cancer. 2013 Oct;23(8):1348. doi: 10.1097/01.IGC.0000434437.52819.d2. No abstract available.

PMID:
24257547
3.

Prognostic impact of the cancer stem cell-related marker NANOG in ovarian serous carcinoma.

Lee M, Nam EJ, Kim SW, Kim S, Kim JH, Kim YT.

Int J Gynecol Cancer. 2012 Nov;22(9):1489-96. doi: 10.1097/IGJ.0b013e3182738307.

PMID:
23095773
4.

Identification of glia maturation factor beta as an independent prognostic predictor for serous ovarian cancer.

Li YL, Ye F, Cheng XD, Hu Y, Zhou CY, Lü WG, Xie X.

Eur J Cancer. 2010 Jul;46(11):2104-18. doi: 10.1016/j.ejca.2010.04.015. Epub 2010 May 22.

PMID:
20547056
5.

Clinical and prognostic significance of lost or decreased PDCD5 expression in human epithelial ovarian carcinomas.

Zhang X, Wang X, Song X, Wei Z, Zhou C, Zhu F, Wang Q, Ma C, Zhang L.

Oncol Rep. 2011 Feb;25(2):353-8. doi: 10.3892/or.2010.1103. Epub 2010 Dec 13.

PMID:
21165576
6.

Expression of the Ets transcription factor EHF in serous ovarian carcinoma effusions is a marker of poor survival.

Brenne K, Nymoen DA, Hetland TE, Trope' CG, Davidson B.

Hum Pathol. 2012 Apr;43(4):496-505. doi: 10.1016/j.humpath.2011.05.023. Epub 2011 Aug 19.

PMID:
21855111
7.

Defining a prognostic marker panel for patients with ovarian serous carcinoma effusion.

Davidson B, Smith Y, Nesland JM, Kærn J, Reich R, Tropè CG.

Hum Pathol. 2013 Nov;44(11):2449-60. doi: 10.1016/j.humpath.2013.06.003. Epub 2013 Sep 5.

PMID:
24011953
8.

[Expression and role of glucose-regulated protein 78 in ovarian serous adenocarcinoma].

Fan LM, Su J, Dong H, Wei M, Cui MH.

Zhonghua Yi Xue Za Zhi. 2013 Mar 5;93(9):659-62. Chinese.

PMID:
23751742
10.

Elevated cyclooxygenase-2 expression is associated with altered expression of p53 and SMAD4, amplification of HER-2/neu, and poor outcome in serous ovarian carcinoma.

Erkinheimo TL, Lassus H, Finne P, van Rees BP, Leminen A, Ylikorkala O, Haglund C, Butzow R, Ristimäki A.

Clin Cancer Res. 2004 Jan 15;10(2):538-45.

11.

HOXB8 expression in ovarian serous carcinoma effusions is associated with shorter survival.

Stavnes HT, Holth A, Don T, Kærn J, Vaksman O, Reich R, Trope' CG, Davidson B.

Gynecol Oncol. 2013 May;129(2):358-63. doi: 10.1016/j.ygyno.2013.02.021. Epub 2013 Feb 21.

PMID:
23438671
12.

Transketolase is upregulated in metastatic peritoneal implants and promotes ovarian cancer cell proliferation.

Ricciardelli C, Lokman NA, Cheruvu S, Tan IA, Ween MP, Pyragius CE, Ruszkiewicz A, Hoffmann P, Oehler MK.

Clin Exp Metastasis. 2015 Jun;32(5):441-55. doi: 10.1007/s10585-015-9718-1. Epub 2015 Apr 21.

PMID:
25895698
13.

[Expression of THY1 gene in epithelial ovarian cancer].

Zeng LQ, Peng ZL, Duan ZL.

Zhonghua Zhong Liu Za Zhi. 2009 Feb;31(2):118-20. Chinese.

PMID:
19538887
14.

HSP60 predicts survival in advanced serous ovarian cancer.

Hjerpe E, Egyhazi S, Carlson J, Stolt MF, Schedvins K, Johansson H, Shoshan M, Avall-Lundqvist E.

Int J Gynecol Cancer. 2013 Mar;23(3):448-55. doi: 10.1097/IGC.0b013e318284308b.

PMID:
23429486
15.

Argonaute, Dicer, and Drosha are up-regulated along tumor progression in serous ovarian carcinoma.

Vaksman O, Hetland TE, Trope' CG, Reich R, Davidson B.

Hum Pathol. 2012 Nov;43(11):2062-9. doi: 10.1016/j.humpath.2012.02.016. Epub 2012 May 29.

PMID:
22647351
16.

BUB1 mRNA is significantly co-expressed with AURKA and AURKB mRNA in advanced-stage ovarian serous carcinoma.

Davidson B, Nymoen DA, Elgaaen BV, Staff AC, Tropé CG, Kærn J, Reich R, Falkenthal TE.

Virchows Arch. 2014 Jun;464(6):701-7. doi: 10.1007/s00428-014-1577-7. Epub 2014 Apr 23.

PMID:
24756216
17.

The potential prognostic value of cathepsin D protein in serous ovarian cancer.

Chai Y, Wu W, Zhou C, Zhou J.

Arch Gynecol Obstet. 2012 Aug;286(2):465-71. doi: 10.1007/s00404-012-2318-2. Epub 2012 Apr 3.

PMID:
22476353
18.

Retinoid receptor alpha and Beta expression in serous ovarian tumors.

Daponte A, Kostopoulou E, Papandreou CN, Chiotoglou I, Voutsadakis I, Vanakara P, Minas M, Nakou M, Kallitsaris A, Kollia P, Koukoulis G, Messinis IE.

Oncology. 2007;73(1-2):81-9. doi: 10.1159/000120633. Epub 2008 Mar 12. Erratum in: Oncology. 2010;78(2):124. Papandreou, C N [added]; Voutsadakis, I [added].

PMID:
18334854
19.

Clinicopathological significance of DEK overexpression in serous ovarian tumors.

Han S, Xuan Y, Liu S, Zhang M, Jin D, Jin R, Lin Z.

Pathol Int. 2009 Jul;59(7):443-7. doi: 10.1111/j.1440-1827.2009.02392.x.

PMID:
19563407
20.

The clinical role of phospholipase A2 isoforms in advanced-stage ovarian carcinoma.

Gorovetz M, Baekelandt M, Berner A, Trope' CG, Davidson B, Reich R.

Gynecol Oncol. 2006 Dec;103(3):831-40. Epub 2006 Aug 17.

PMID:
16919315
Format
Items per page
Sort by

Send to:

Choose Destination

Supplemental Content

Write to the Help Desk